{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["9"],"submitter":["Pierce D"],"pubmed_abstract":["<h4>Background</h4>About 30% of patients with gastroesophageal reflux disease continue to experience symptoms despite treatment with proton pump inhibitors. The 5-hydroxytryptamine 4 receptor agonist revexepride (SSP-002358) is a novel prokinetic that stimulates gastrointestinal motility, which has been suggested as a continued cause of symptoms in these patients. The aim of this study was to assess whether revexepride pharmacokinetics were affected by co-administration of omeprazole, in preparation for a proof-of-concept evaluation of revexepride added to proton pump inhibitor treatment.<h4>Methods</h4>In this phase 1, open-label, randomized, two-period crossover study, healthy adults aged 18-55 years were given a single dose of revexepride 1 mg or revexepride 1 mg + omeprazole 40 mg. Pha"],"journal":["Drug design, development and therapy"],"pagination":["1257-68"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4354395"],"repository":["biostudies-literature"],"pubmed_title":["A phase 1 randomized study evaluating the effect of omeprazole on the pharmacokinetics of a novel 5-hydroxytryptamine receptor 4 agonist, revexepride (SSP-002358), in healthy adults."],"pmcid":["PMC4354395"],"pubmed_authors":["Velinova M","Hossack S","Hoppenbrouwers M","Pierce D","Martin P","Corcoran M"],"additional_accession":[]},"is_claimable":false,"name":"A phase 1 randomized study evaluating the effect of omeprazole on the pharmacokinetics of a novel 5-hydroxytryptamine receptor 4 agonist, revexepride (SSP-002358), in healthy adults.","description":"<h4>Background</h4>About 30% of patients with gastroesophageal reflux disease continue to experience symptoms despite treatment with proton pump inhibitors. The 5-hydroxytryptamine 4 receptor agonist revexepride (SSP-002358) is a novel prokinetic that stimulates gastrointestinal motility, which has been suggested as a continued cause of symptoms in these patients. The aim of this study was to assess whether revexepride pharmacokinetics were affected by co-administration of omeprazole, in preparation for a proof-of-concept evaluation of revexepride added to proton pump inhibitor treatment.<h4>Methods</h4>In this phase 1, open-label, randomized, two-period crossover study, healthy adults aged 18-55 years were given a single dose of revexepride 1 mg or revexepride 1 mg + omeprazole 40 mg. Pha","dates":{"release":"2015-01-01T00:00:00Z","publication":"2015","modification":"2025-04-05T16:02:38.662Z","creation":"2019-03-27T01:47:53Z"},"accession":"S-EPMC4354395","cross_references":{"pubmed":["25767373"],"doi":["10.2147/DDDT.S64621"]}}